C4 Therapeutics Inc
Monthly Stock Prices Chart
This stock price chart for C4 Therapeutics Inc, symbol CCCC, Nasdaq Stock Exchange is updated
monthly.
TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes.
[Add symbol to "MyMenu"]
Daily and Weekly charts are also available for C4 Therapeutics Inc.
Most Recent HeadlinesMNA: Dec 8th, 2024, 23:47Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 22:50Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 21:55Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 21:00Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 20:05Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 19:09Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 18:14Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 17:16Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 16:20Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 DegraderMNA: Dec 8th, 2024, 15:26Length: 16773 C4 Therapeutics Presents Cemsidomide Phase 1 Data At The American Society For Hematology (ASH) Annual Meeting That Demonstrated Potential To Become Best-In-Class IKZF1/3 Degrader
|
